Which patients is suitable for Acemini?

Aximini is mainly suitable for adult patients diagnosed with chronic myelogenous leukemia (CML) in the chronic phase (CP) or blast phase (AP), especially those who are ineffective or resistant to previous treatments. The most important indication is for patients with T315I mutation. T315I is a common and serious BCR-ABL mutation in chronic myelogenous leukemia. Traditional TKI treatment is often difficult to effectively control. Aceminib can overcome this resistance mutation through its unique mechanism of action. In addition, acemini is also suitable for patients whose condition fails to be effectively relieved after multiple lines of TKI treatment. Clinical studies have shown that for patients who have not achieved complete cytogenetic remission (CCyR) after receiving at least two TKI treatments, aceminib is highly effective and can help patients regain disease control.